Office of Surveillance and Epidemiology 2023 Annual Report

https://www.fda.gov/media/180347/download?attachment=&utm_medium=email&utm_source=govdelivery The Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology (OSE) is pleased to share its 2023 Annual Report. During 2023, OSE redoubled its commitment to integrating technology in the pursuit of enhancing public health with an emphasis on improving medication safety. A few examples of OSE’s technology milestones included development of: Machine learning for medical chart review as part of our work with the Sentinel Innovation Center to reduce manual review and streamline operations, The Information Visualization Platform, built on artificial intelligence, to de-duplicate the FDA Adverse Event Reporting System (FAERS) database and incoming FAERS reports. OSE also continued to play a significant role in the safety analysis of drugs before and after they are marketed. OSE contributed to 55 novel drug approvals and utilized post marketing data to identify or evaluate 60 Newly Identified Safety Signals for marketed drugs. View the full OSE 2023 Annual Report for more on OSE’s unwavering commitment to advancing public health.